Tian An Medicare: Losses, No Analyst Coverage, And A Thin Case For Buying The Dip

Tian An Medicare (HKEX: 383) sets an August board meeting to approve its H1 2026 interim results. For a stock that has dropped from a 52-week high of HK$1.36 to roughly HK$0.81 - about 40 percent lower - that meeting is the first real checkpoint in months. The interim numbers will show whether the business stopped sliding or just found a lower floor. Until then, the risk/reward does not support a Buy.

The Recent Context

The past five months have been noisy for Tian An Medicare. Shares were halted on March 16, 2026, and resumed on March 23 when the company unveiled a HK$77 million share buyback - 70 million shares at HK$1.10 each, roughly 6.5 percent of the issued share count. The buyback was executed in early June. Management was signaling that HK$1.10 was a fair price. The market disagreed. The stock has drifted down from there to trade near its 52-week low around HK$0.81-0.85.

That divergence between management's buyback price and the current share price is a classic test. A buyback at a premium to the prevailing market price can be a genuine vote of confidence - or it can be a one-time capital gesture that runs out of oxygen. On a market cap of roughly HK$818 million, HK$77 million is material but not transformative. And the stock's trajectory since the buyback closed suggests the market saw it as the former, not the latter.

The Operating Picture Is Thin

Tian An Medicare - formerly China Medical & HealthCare Group, renamed in May 2024 - runs six business segments: hospitals in mainland China, eldercare property development, general property development, property investment and leasing, financial services lending, and securities trading. That is a diversified holding company structure, which in practice means no single engine is driving growth and every segment dilutes the others.

The full-year 2025 results, approved at the March board meeting, were not encouraging. Revenue came in at HK$1.64 billion, flat on FY2024. The company swung to a net loss of HK$26.8 million - a loss per share of HK$0.025 - versus a small profit of HK$0.026 per share the year before. The first half of 2024 had also been a loser, with a net loss of roughly HK$37.8 million. So the full year 2025 turned negative, even though revenue did not contract.

Revenue flat while profitability deteriorates is a pattern that deserves scrutiny. It usually means cost inflation, lower-margin segment mix, or one-off charges eating into what used to be thin operating profit. Without segment-level detail from the interim announcement, there is no way to know which segment is the drag and which, if any, is a bright spot. The upcoming H1 2026 results will need to address that.

Valuation Does Not Save It

There is no price-to-earnings multiple to cite - the company is loss-making. There is no analyst consensus. There is no dividend. The stock trades at a market cap of roughly HK$818 million on HK$1.64 billion in revenue, or about 0.5x trailing sales. That sounds cheap, but cheap on a declining business with no visible growth engine is not the same as undervalued. A low sales multiple on a loss-making healthcare operator with a conglomerate structure is not an anomaly to exploit - it is what the market assigns to businesses it cannot figure out.

The buyback at HK$1.10 implied a market cap closer to HK$1.1 billion. The current price of roughly HK$0.81 has erased that premium entirely. Management's conviction was priced in, then immediately rejected.

What Would Change My View

The August interim results matter. Specifically:

• Revenue growth or at least stabilization in the hospital and healthcare segment, which is the core business. If hospital revenue is falling while the company props up the top line with property or financial services, that is not a durable story.
• Evidence the net loss has narrowed or reversed. The company does not need to be a growth compounder, but it needs to be profitable to deserve any multiple expansion.
• A clear capital allocation plan beyond the one-time buyback. Is management planning to divest non-core segments? Consolidate operations? Raise prices in its hospital business?

If the interim results show the hospital segment growing, losses narrowing materially, and a coherent strategy for the holding company structure, I would reconsider. If the results show continued flat-to-declining revenue with losses persisting, the current price may still have room to fall.

Rating: Hold

Tian An Medicare is a small-cap Hong Kong healthcare holding company that has lost its way operationally and has no catalyst visible outside the upcoming interim results. The 40 percent selloff from the 52-week high has compressed the valuation, but it has not yet priced in a business that is clearly improving. The buyback gesture was real, but the market's response - lower prices since June - is also real. Wait for the August results to prove the turn before stepping in.